Radiation Therapy for Carcinoma, Non-Small-Cell Lung

Phase-Based Estimates
Holden Comprehensive Cancer Cener, Iowa City, IA
Carcinoma, Non-Small-Cell Lung+3 More
Radiation Therapy - Drug
All Sexes
Eligible conditions
Carcinoma, Non-Small-Cell Lung

Study Summary

This study is evaluating whether high-dose vitamin C may help improve outcomes for individuals with non-small cell lung cancer.

See full description

Eligible Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Lung Cancer
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Lung Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Radiation Therapy will improve 1 primary outcome and 4 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of 3 to 4 weeks after last radiation treatment.

Week 4
Progression rate at completion of radiation and chemotherapy
Year 20
Progression free survival (PFS)
Tumor response
Year 20
Overall survival (OS)
Year 2
Adverse event frequency and categorization

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

2 Treatment Groups

ChemoRT + Ascorbate

This trial requires 46 total participants across 2 different treatment groups

This trial involves 2 different treatments. Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

ChemoRT + AscorbateRadiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
ControlNo treatment in the control group
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation Therapy
Completed Phase 3
FDA approved
Ascorbic acid
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: weekly for the first 7 weeks, then monthly for 3 months, then every 6 months through 2 years post-treatment
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly weekly for the first 7 weeks, then monthly for 3 months, then every 6 months through 2 years post-treatment for reporting.

Who is running the study

Principal Investigator
B. A.
Prof. Bryan Allen, Assistant Professor, Department of Radiation Oncology
University of Iowa

Closest Location

Holden Comprehensive Cancer Cener - Iowa City, IA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Tumor or metastatic disease must measure at least 1 cm using a CT scan (CAT scan)
Note: patients who have a small pleural effusion that is too small to safety tap and is not visible on a chest x-ray are still eligible
Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) of non-small cell lung cancer.
Recommended to receive carboplatin & paclitaxel with radiation therapy as a treatment
Physician determined the patient is healthy enough for chemotherapy and radiation therapy
At least part of the lung cancer must be viewable and measurable by CT or MRI
A platelet count of at least 100,000 cells per mililiter
A creatinine level of less than 1 1/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)
Not pregnant, and commit to using birth control during the study

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get carcinoma, non-small-cell lung a year in the United States?

Add answer

[Incidence/yr and deaths/yr.] The incidence of lung carcinoma, not of histology, was significantly higher for women and for Asians/Pacific Islanders. A significantly higher rate of carcinoma death among African Americans was observed for whites compared to Chinese/Filipino and Japanese/Korean (p < 0.05). A lower rate of lung cancer death among Caucasian women was observed in the Hispanic/Latino group than in those of Japanese ethnic background (p = 0.02). Among Japanese/Korean women, the incidence ratio of lung carcinoma death was 3.0 times greater for current smokers.

Unverified Answer

Can carcinoma, non-small-cell lung be cured?

Add answer

The current study demonstrates that patients with non-small-cell lung cancer treated with chemotherapy are significantly more likely to be alive 10 years post surgery as compared to patients with non-small-cell lung cancer who did not receive chemotherapy. These data suggest that non-small-cell lung cancer can be cured in some patients.

Unverified Answer

What is carcinoma, non-small-cell lung?

Add answer

Lung carcinoma, a type of cancer, is more common in men than women. The overall proportion is 11.1 per 1000 men, while only 1.8 per 1000 women. Tobacco use is also more common among men, at 60.4 per 1000 men. The 5-year survival rates in the USA are 74.0 in men and 59.7 in women. In the United Kingdom, the five-year survival is only 59.8 out of 100,000 in men and 54.7 per 100,000 women.

Unverified Answer

What are common treatments for carcinoma, non-small-cell lung?

Add answer

Carcinoma, non-small-cell lung was often treated with chemotherapy such as carboplatinum or cisplatin or targeted therapy such as erlotinib; however, some treatments such as radiation therapy/brachytherapy were less commonly used. Clinical trials were more common for breast cancer than for carcinoma, non-small-cell lung. Physicians usually discuss treatment with their patients, and patients often express treatment preferences.

Unverified Answer

What causes carcinoma, non-small-cell lung?

Add answer

Data from a recent study indicated that the main factors that contribute to the risk of developing carcinoma, non-small cell lung were old age at diagnosis and smoking. Data from a recent study may therefore have important implications in deciding which factors to target in primary and secondary prevention of non-small cell lung cancer.

Unverified Answer

What are the signs of carcinoma, non-small-cell lung?

Add answer

Signs of cancer are not all specific to that particular type of cancer. Common signs include swelling/distension of the neck, neck lump, or, in cases of lung cancer, chest wall pain, which may result in weight loss. Tests such as CT scan, X-ray scan or MRI are other signs of carcinoma, non-small-cell lung.

Unverified Answer

What is the latest research for carcinoma, non-small-cell lung?

Add answer

These recent studies on cancer research, as reported to the journal OncoLink, had a significant impact on our patients with NSCLC. Thus, there is strong evidence that these studies will have a significant impact on the overall care of patients with NSCLC.

Unverified Answer

Does radiation therapy improve quality of life for those with carcinoma, non-small-cell lung?

Add answer

Quality of life is significantly improved in the first six months following RT for carcinoma, NSCLC. The majority of those who report improvement in quality of life are satisfied with the gains.

Unverified Answer

What is the survival rate for carcinoma, non-small-cell lung?

Add answer

The overall 5-year survival rate in the United States was 31% for all lung cancers and 35% for small cell lung cancer and 11% for non-small cell lung cancer. Among the nonsmall cell lung cancers, the prognostic value of subgroup analyses remained significant.

Unverified Answer

What are the common side effects of radiation therapy?

Add answer

For RT, the most common side effects in NSCLC patients are acute chest discomfort or shortness of breath, rash, loss of appetite, fatigue, nausea, dyspepsia or heartburn, coughs, and a headache. Patients with a history of asthma are more likely to develop acute bronchitis.

Unverified Answer

What is the primary cause of carcinoma, non-small-cell lung?

Add answer

These data suggest that carcinoma, non-small-cell lung progresses through two distinct phases, an invasive invasive phase and a noninvasive metastatic phase, both of which are associated with different molecular changes.

Unverified Answer

Who should consider clinical trials for carcinoma, non-small-cell lung?

Add answer

We found that the majority of respondents to our survey had no prior experiences or knowledge with clinical trials in the area of cancer, non-small cell lung. However, all respondents claimed their comfort level for the topic of cancer/NSCLC clinical trials was low and [for patients not enrolled in a trial, 98% said they wanted to enroll in one] which could be a contributing reason for such a lack of awareness.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Non-Small-Cell Lung by sharing your contact details with the study coordinator.